-
Company Insights
Innovation and Patenting activity of Nissei Asb Machine Co., Ltd. Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Nissei Asb Machine Co., Ltd. Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Afuresertib Hydrochloride in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afuresertib Hydrochloride in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afuresertib...
-
Analyst Opinions
New Zealand Retail Banking Competitor Benchmarking – Financial Performance, Customer Relationships and Satisfaction
New Zealand Retail Banking Market Report Overview All banks in New Zealand improved their profitability in 2022, with 2023 having a more mixed outlook due to rate-induced recession. Despite the turbulent property landscape in New Zealand, all banks experienced growth in their TDA and net interest income. The highest level of concentration in the New Zealand retail banking sector continues to be held by the top four providers. Although New Zealand is known for having a significantly high market concentration,...
-
Sector Analysis
New Zealand Cards and Payments – Opportunities and Risks to 2027
New Zealand Cards and Payments Market Report Overview The annual value of card transactions in the New Zealand cards and payments market is estimated to be $65 billion in 2023 and is expected to grow at a CAGR of more than 4% during 2023-2027. The New Zealand cards and payments market research report provides a detailed analysis of market trends in the New Zealand cards and payments industry. It provides values and volumes for several key performance indicators in the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afuresertib Hydrochloride in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afuresertib Hydrochloride in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Afuresertib Hydrochloride in Endometrial Cancer Drug Details: Afuresertib hydrochloride (GSK2110183, ASB-183) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afuresertib Hydrochloride in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afuresertib Hydrochloride in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Afuresertib Hydrochloride in Triple-Negative Breast Cancer (TNBC) Drug Details: Afuresertib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afuresertib Hydrochloride in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afuresertib Hydrochloride in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Afuresertib Hydrochloride in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afuresertib Hydrochloride in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afuresertib Hydrochloride in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Afuresertib Hydrochloride in Solid Tumor Drug Details: Afuresertib hydrochloride (GSK2110183, ASB-183) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afuresertib Hydrochloride in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afuresertib Hydrochloride in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Afuresertib Hydrochloride in Gastric Cancer Drug Details: Afuresertib hydrochloride (GSK2110183, ASB-183) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afuresertib Hydrochloride in Squamous Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afuresertib Hydrochloride in Squamous Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Afuresertib Hydrochloride in Squamous Non-Small Cell Lung Carcinoma Drug...